Skip to main content

Table 4 COX-2 .8473 genotype, NSAIDs use, and risk for breast cancer by hormone receptor status, Long Island Breast Cancer Study Project, 1996–1997

From: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk

COX-2 .8473 genotype

Aspirin/any NSAID

No use

Ever use

  

Cases/controls

OR (95% CI)a

Cases/controls

OR (95% CI)a

ER or PR positive

   TT

Aspirin

191/332

1.0 (ref.)

46/101

0.7 (0.5–1.0)

   TC + CC

 

237/439

1.0 (0.7–1.2)

61/148

0.6 (0.4–0.9)b

   TT

Any NSAID

147/285

1.0 (ref.)

92/155

1.1 (0.8–1.5)

   TC + CC

 

210/371

1.1 (0.9–1.5)

89/223

0.7 (0.5–1.0)c

ER and PR negative

   TT

Aspirin

44/332

1.0 (ref.)

13/101

1.0 (0.5–1.8)

   TC + CC

 

53/439

0.9 (0.6–1.4)

22/148

1.1 (0.6–1.9)d

   TT

Any NSAID

40/285

1.0 (ref.)

18/155

0.8 (0.5–1.5)

   TC + CC

 

39/371

0.8 (0.5–1.2)

37/223

1.2 (0.7–1.9)e

  1. aAdjusted for age at reference. bMultiplicative interaction term was not significant (P for interaction = 0.78) by Wald statistic. cMultiplicative interaction term was significant (P for interaction = 0.02) by Wald statistic. dMultiplicative interaction term was not significant (P for interaction = 0.59) by Wald statistic. eMultiplicative interaction term was not significant (P for interaction = 0.10) by Wald statistic. CI, confidence interval; ER, estrogen receptor; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; PR, progesteron receptor.